Skip to content

S. 148 · 118th Congress (2023–2025)

Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Show official title

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReported by committee

This bill’s path

This is S. 148’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Amy Klobuchar (D-MN)
Cosponsors
8 cosponsors

6 original · 2 later

3 R · 5 D

  1. Sen. Richard Blumenthal (D-CT)· Original · Jan 30, 2023
  2. Sen. Cory A. Booker (D-NJ)· Original · Jan 30, 2023
  3. Sen. Mike Braun (R-IN)· Original · Jan 30, 2023
  4. Sen. Ted Cruz (R-TX)· Original · Jan 30, 2023
  5. Sen. Richard J. Durbin (D-IL)· Original · Jan 30, 2023
  6. Sen. Chuck Grassley (R-IA)· Original · Jan 30, 2023
  7. Sen. Jon Ossoff (D-GA)· Later · Feb 1, 2023
  8. Sen. Peter Welch (D-VT)· Later · Feb 9, 2023
Policy area
Health
Subjects
  • Administrative remedies
  • Business ethics
  • Civil actions and liability
  • Competition and antitrust
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Licensing and registrations
  • 2 more
    • Prescription drugs
    • Public participation and lobbying

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Jan 30, 2023 – Mar 1, 2023
    1. Referred to committee

      Read twice and referred to the Committee on the Judiciary.

      Sources
    2. Ordered reported

      Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

      Sources
    3. Reported by committee

      Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.

      Sources
  3. Expired

    Introduced → Reported by committee → No further action before the 118th Congress ended.

Committees

  1. SenateJudiciaryReferred Jan 30, 2023 · Markup Feb 9, 2023 · Reported Mar 1, 2023
    1. Feb 9, 2023 · Meeting

      Business meeting to consider committee rules, an original resolution authorizing expenditures by the committee for the 118th Congress, S.79, to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, S.113, to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, S.142, to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products, S.148, to enable to Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, S.150, to amend the Federal Trade Commission Act to prohibit product hopping, and the nominations of Nancy G. Abudu, of Georgia, to be United States Circuit Judge for the Eleventh Circuit, Rachel Bloomekatz, of Ohio, to be United States Circuit Judge for the Sixth Circuit, Anthony Devos Johnstone, of Montana, to be United States Circuit Judge for the Ninth Circuit, Julie Rikelman, of Massachusetts, to be United States Circuit Judge for the First Circuit, Robert Stewart Ballou, to be United States District Judge for the Western District of Virginia, Nusrat Jahan Choudhury, Natasha C. Merle, and Ramon Ernesto Reyes, Jr., each to be United States District Judge for the Eastern District of New York, Jessica G. L. Clarke, Dale E. Ho, and Arun Subramanian, each to be a United States District Judge for the Southern District of New York, Todd E. Edelman, to be United States District Judge for the District of Columbia, Kymberly Kathryn Evanson, to be United States District Judge for the Western District of Washington, Gordon P. Gallagher, to be United States District Judge for the District of Colorado, Jonathan James Canada Grey, to be United States District Judge for the Eastern District of Michigan, Myong J. Joun, and Julia E. Kobick, both to be a United States District Judge for the District of Massachusetts, Kenly Kiya Kato, and Hernan D. Vera, both to be a United States District Judge for the Central District of California, Colleen R. Lawless, to be United States District Judge for the Central District of Illinois, Rita F. Lin, and P. Casey Pitts, both to be a United States District Judge for the Northern District of California, Andrew G. Schopler, and James Edward Simmons, Jr., both to be a United States District Judge for the Southern District of California, and Rosemarie Hidalgo, of the District of Columbia, to be Director of the Violence Against Women Office, Amy Lefkowitz Solomon, of the District of Columbia, to be an Assistant Attorney General, Kate E. Brubacher, to be United States Attorney for the District of Kansas, Ismail J. Ramsey, to be United States Attorney for the Northern District of California, and Jill E. Steinberg, to be United States Attorney for the Southern District of Georgia, all of the Department of Justice.

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (3)
  1. Stop STALLING Act

    Display title, Short title · Introduced in Senate, Reported to Senate

  2. Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

    Short title · Introduced in Senate, Reported to Senate

  3. A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

    Official title · Introduced in Senate